Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning

Haematologica

Volumn 97, Issue 5, 2012, Pages 710-716

  Konopacki, Johanna ^a   Porcher, Raphaël ^b   Robin, Marie ^a   Bieri, Sabine ^c   Cayuela, Jean Michel ^a   Larghero, Jérôme ^b   Xhaard, Aliénor ^a   Andreoli, Anna Lisa ^a   Dhedin, Nathalie ^a   Petropoulou, Anna ^a   Rodriguez Otero, Paula ^a   Ribaud, Patricia ^a   Moins Teisserenc, Hélène ^d   Carmagnat, Maryvonnick ^d   Toubert, Antoine ^d   Chalandon, Yves ^c   Socie, Gérard ^a,b,d   de Latour, Régis Peffault ^a,d  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d INSERM   (France)

Author keywords

Hematopoietic stem cell transplantation; Long term outcomes; Severe aplastic anemia

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; AVASCULAR NECROSIS; B LYMPHOCYTE; BASAL CELL CARCINOMA; BONE NECROSIS; CARDIOVASCULAR DISEASE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRESCHOOL CHILD; SCHOOL CHILD; THROMBOCYTE COUNT; UTERINE CERVIX CARCINOMA;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84860595768     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.050096     Document Type: Article

References (41)

1. Mathe G, Amiel JL, Schwarzenberg L, Choay J, Trolard P, Schneider M, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J. 1970;2 (5702):131-6.
2. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H; German Aplastic Anemia Study G. Antithymocyte globulin with or without cyclosporin A: 11-year follow- up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003; 101(4):1236-42.
3. Bacigalupo A. Treatment strategies for patients with severe aplastic anemia. Bone Marrow Transplant. 2008;42 (Suppl 1):S42-S4.
4. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclo - sporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289(9): 1130-5.
5. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-19.
6. Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI, et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood. 1997;89(10):3890-1.
7. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant. 2001;7(1):39-44.
8. Cohen A, Bekassy AN, Gaiero A, Faraci M, Zecca S, Tichelli A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant. 2008;41 (Suppl 2):S43-8.
9. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397-400.
10. Locatelli F, Bruno B, Zecca M, Van-Lint MT, McCann S, Arcese W, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96(5):1690-7.
11. Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11-8.
12. Marsh JC, Ball SE, Darbyshire P, Gordon- Smith EC, Keidan AJ, Martin A, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol. 2003;123(5):782-801.
13. Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP, et al. Longterm outcome after marrow transplantation for severe aplastic anemia. Blood. 1998;91(10):3637-45.
14. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-8.
15. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-56.
16. Corre E, Carmagnat M, Busson M, de Latour RP, Robin M, Ribaud P, et al. Longterm immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections. Haematologica. 2010;95(6):1025-9.
17. Kalbfleisch P. The Statistical Analysis of Failure Time Data. Sons JW, editor. New York 1980.
18. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. 1978;(34):541-54.
19. Grambsch T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;(81):515-56.
20. R: A Language and Environment for Statistical Computing. [database on the Internet]. R Foundation for Statistical Computing. 2009. Available from: URL http://www.R-project.org.
21. Gluckman E, Socie G, Devergie A, Bourdeau-Esperou H, Traineau R, Cosset JM. Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow- up. Blood. 1991;78(9):2451-5.
22. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000;37 (1):30-42.
23. Storb R, Epstein RB, Rudolph RH, Thomas ED. The effect of prior transfusion on marrow grafts between histocompatible canine siblings. J Immunol. 1970;105(3):627-33.
24. Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med. 1977;296(2):61-6.
25. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, Cahn JY. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341(1):14-21.
26. Bacigalupo A, Brand R, Oneto R, Bruno B, Socié G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Seminar Hematol. 2000;37(1):69-80.
27. Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103(7):2490-7.
28. Campbell S, Sun CL, Kurian S, Francisco L, Carter A, Kulkarni S, et al. Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation. Cancer. 2009;115(18):4127-35.
29. Socie G, Cahn JY, Carmelo J, Vernant JP, Jouet JP, Ifrah N, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol. 1997;97 (4):865-70.
30. Marsh JC, Zomas A, Hows JM, Chapple M, Gordon-Smith EC. Avascular necrosis after treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone. Br J Haematol. 1993; 84(4):731-5.
31. Socie G, Selimi F, Sedel L, Frija J, Devergie A, Esperou Bourdeau H, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. Br J Haematol. 1994;86(3):624-8.
32. Petropoulou AD, Porcher R, Herr AL, Devergie A, Brentano TF, Ribaud P, et al. Prospective assessment of bone turnover and clinical bone diseases after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;89(11):1354-61.
33. Baker KS, Ness KK, Steinberger J, Carter A, Francisco L, Burns LJ, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007;109 (4):1765-72.
34. Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110(9):3463-71.
35. Tichelli A, Passweg J, Wojcik D, Rovo A, Harousseau JL, Masszi T, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93(8):1203-10.
36. Storek J, Joseph A, Espino G, Dawson MA, Douek DC, Sullivan KM, et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood. 2001;98(13):3505-12.
37. Passweg JR, Socie G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM, et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved?. Blood. 1997;90(2):858-64.
38. Bacigalupo A, Oneto R, Bruno B, Socie G, Passweg J, Locasciulli A, et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol. 2000;103(1):19-25.
39. Bacigalupo A. Guidelines for the treatment of severe aplastic anemia. Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of Bone Marrow Transplantation (EBMT). Haematologica. 1994;79(5):438-44.
40. Locasciulli A, van't Veer L, Bacigalupo A, Hows J, Van Lint MT, Gluckman E, et al. Treatment with marrow transplantation or immunosuppression of childhood acquired severe aplastic anemia: a report from the EBMT SAA Working Party. Bone Marrow Transplantation. 1990;6(3):211-7.
41. Marsh JC, Gupta V, Lim Z, Ho AY, Ireland R, Hayden J, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118 (8):2351-7.